On October 7, 2021 Shanghai’s Zai Lab reported its in-licensed HER2 drug met its endpoints in patients with previously treated HER2+ breast cancer. Zai acquired China rights to margetuximab as part of a $165 million, three-drug deal from MacroGenics in 2018 (Press release, Zai Laboratory, OCT 7, 2021, View Source [SID1234591033]). MacroGenics was approved to launch margetuximab in the US last year in combination with chemotherapy as a third-line treatment for HER2 positive breast cancer. Zai plans to file a BFA in China before the end of the year.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!